Explore dapagliflozin in symptomatic heart failure with reduced ejection fraction and Type 2 Diabetes
Webinar with Dr Ted Wu and Prof Andrew Sindone introducing the DAPA-HF study and the evidence for Forxiga (dapagliflozin) for the treatment of symptomatic heart failure with reduced ejection fraction in adults with or without t2d. Also looks at the evidence beyond HbA1c in Type 2 Diabetes.